Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
NCT ID: NCT07222995
Last Updated: 2025-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
2900 participants
INTERVENTIONAL
2025-10-10
2030-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention
NCT00709306
Undergraduate Skin Cancer Prevention Trial
NCT05634252
A Motivational Enhancement Approach to Skin Cancer Prevention
NCT00705887
Educational Intervention on Skin Cancer Protective Behaviors Among Female Healthcare Workers
NCT07139119
UV Dosimetry Feedback in NMSC Patients
NCT03757663
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Precision Prevention Intervention
Participants receive personalized skin cancer prevention materials based on MC1R genetic risk.
Precision Prevention Booklet
Precision prevention booklet anchored in their MC1R risk that incorporates gold-standard risk communication strategies, including visual risk representations and simple language.
Standard Prevention
Participants receive standard skin cancer prevention materials.
Standard Prevention Booklet
Standard materials are similar in content to the precision prevention booklet but without any reference to MC1R risk.
Non-Intervention
Participants who do not return saliva kits will not receive intervention materials but will complete follow-up assessments.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Precision Prevention Booklet
Precision prevention booklet anchored in their MC1R risk that incorporates gold-standard risk communication strategies, including visual risk representations and simple language.
Standard Prevention Booklet
Standard materials are similar in content to the precision prevention booklet but without any reference to MC1R risk.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be 18 years of age or older.
* Self-report skin cancer risk behaviors within the past 12 months, including: Intentional sun exposure (e.g., outdoor or indoor tanning) or unintentional sun exposure leading to sunburn.
* Be willing to complete a baseline questionnaire and provide a saliva sample for MC1R genotyping.
* Be able to provide informed consent (written or electronic).
* Prefer English or Spanish for communication and study materials.
Exclusion Criteria
* Are unwilling or unable to complete the baseline assessment or return the saliva kit.
* Decline to provide informed consent.
* Are under 18 years of age.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Kanetsky, PhD, MPH
Role: PRINCIPAL_INVESTIGATOR
Moffitt Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moffitt Cancer Center
Tampa, Florida, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCC-23436
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.